A Phase 2 interventional study of TNP-2092 and Vancomycin in Skin and Subcutaneous Tissue Bacterial Infections and Gram-Positive Bacterial Infections, sponsored by TenNor Therapeutics Limited. Completed at 1 site in United States. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2023-12-01.
Sponsored by TenNor Therapeutics Limited · Phase 2, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 22 studies in Gram-Positive Bacterial Infections with a site in United States — none open to participants now, none under way, none of them phase 3. Gram-Positive Bacterial Infections · United States.
Among the 22 studies in Gram-Positive Bacterial Infections with a site in United States, this one is the 9th largest by enrollment of the 19 interventional ones that give a count, is the only one that started in 2019, is one of 8 in phase 2, and was the 19th registered.
58 studies on the registry are indexed under Gram-Positive Bacterial Infections; 6 are open to participants now.
Browse Gram-Positive Bacterial Infections studies →None of the 22 studies in Gram-Positive Bacterial Infections with a site in United States is open now. The open studies under Gram-Positive Bacterial Infections, anywhere →
Of the 2 Gram-Positive Bacterial Infections studies recruiting now, 2 set no upper age limit and none stop at 75 or younger; none take children under 18; none take healthy volunteers.
This study: 18 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
22 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 4 · Phase 2 9 · Phase 3 6 · Phase 4 1
First in 2000; this study’s year is marked. 1 started in 2019.
This study's enrollment of 120 is above the median of 93 across 40 interventional studies indexed under Gram-Positive Bacterial Infections.
Median enrollment 75 across the 19 interventional studies, 470 across the 2 observational. Of the 22 that completed or were terminated, 12 (55%) have results posted.
This tab as a report to print or save as PDF → With an account.
18 of 22 have an industry lead sponsor. The 10 most frequent:
TenNor Therapeutics Limited is the lead sponsor of 3 studies on the registry; none are open to participants now.
TenNor Therapeutics Limited has 1 study filed under Gram-Positive Bacterial Infections — fewer than ten, so there is no comparison to draw.
None of the studies under way reaches primary completion within a year.
Among the 22 studies in Gram-Positive Bacterial Infections with a site in United States, from their registry updates:
Nothing recorded among them since 2026-09-25.
This tab as a report to print or save as PDF → With an account.
The purpose of this study is to evaluate safety, tolerability, pharmacokinetic characteristics and efficacy of TNP-2092 in adults with ABSSSI suspected or confirmed to be caused by gram-positive pathogens.
This Phase 2, double-blind, randomized, multicenter, parallel, controlled study is conducted to evaluate safety, tolerability, pharmacokinetics and efficacy of TNP-2092, and vancomycin in adults with ABSSSI suspected or confirmed to be caused by gram-positive pathogens. The duration of the treatment period is a minimum of 7 days and a maximum of 14 days.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Subjects may be included in the study if they meet all of the following inclusion criteria:
Exclusion Criteria:
Subjects will be excluded from the study if any of the following exclusion criteria apply prior to randomization:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hypersensitivity
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
TNP-2092 300 mg intravenous every 12 hours
Drug: TNP-2092
vancomycin 1 g intravenous every 12 hours
Drug: Vancomycin
TNP-2092 100mg/vial
Vancomycin 1g/vial
Early Clinical Response at the Early Assessment (EA) Visit in the Intent-to-Treat (ITT) Population
Early clinical response is defined as responder meeting two criteria: (1) patient had at least a 20% reduction of acute bacterial skin and skin structure infection (ABSSSI) primary lesion size compared to baseline measurements; (2) patient did not die of any cause within 72 hours of the first dose of study treatment. An indeterminate classification is used for a response that could not be adequately inferred because study data are unavailable for evaluation of efficacy for any reason (eg, missing data, lost to follow-up, did not attend the EA clinic appointment), or if the early assessment visit is out of the 48 to 72 hours window after the intravenous study treatment starts.
Time frame: 48 to 72 hours after the first dose of study treatment
Early Clinical Response at the Early Assessment Visit in the Modified Intent-to-Treat (mITT) Population
Early clinical response is defined as responder meeting two criteria: (1) patient had at least a 20% reduction of acute bacterial skin and skin structure infection (ABSSSI) primary lesion size compared to baseline measurements; (2) patient did not die of any cause within 72 hours of the first dose of study treatment. An indeterminate classification is used for a response that could not be adequately inferred because study data are unavailable for evaluation of efficacy for any reason (eg, missing data, lost to follow-up, did not attend the EA clinic appointment), or if the early assessment visit is out of the 48 to 72 hours window after the intravenous study treatment starts.
Time frame: 48 to 72 hours after the first dose of study treatment
Early Clinical Response at the Early Assessment Visit in the Micro-Intent-to-Treat (Micro-ITT) Population
Early clinical response is defined as responder meeting two criteria: (1) patient had at least a 20% reduction of acute bacterial skin and skin structure infection (ABSSSI) primary lesion size compared to baseline measurements; (2) patient did not die of any cause within 72 hours of the first dose of study treatment. An indeterminate classification is used for a response that could not be adequately inferred because study data are unavailable for evaluation of efficacy for any reason (eg, missing data, lost to follow-up, did not attend the EA clinic appointment), or if the early assessment visit is out of the 48 to 72 hours window after the intravenous study treatment starts.
Time frame: 48 to 72 hours after the first dose of study treatment
Investigator Assessment of Clinical Response at Post Treatment Evaluation (PTE) Visit in the mITT Population
At the PTE Visit the investigator indicated one of the following outcomes relating to the primary infection under study: Clinical Success: participant was alive; the ABSSSI sufficiently resolved such that further antibacterial therapy is not needed. Clinical Failure: any of the following: (1)Investigator discontinued study treatment and indicated that the ABSSSI had responded inadequately such that alternative (rescue) non-study antibacterial therapy was needed; (2)participant received antibacterial therapy for a different infection that may be effective for the ABSSSI under study; (3) participant developed an adverse event (AE) that required discontinuation of study treatment before completion of the planned treatment regimen; (4) unplanned major surgical treatment for the ABSSSI under study; (5) participant died of any cause up to the specified visit. Indeterminate: study data are unavailable for evaluation of efficacy for any reason (eg, missing data, lost to follow-up).
Time frame: 7 to 14 days after the end of study treatment
Investigator Assessment of Clinical Response at Post Treatment Evaluation (PTE) Visit in the Micro-ITT Population
At the PTE Visit the investigator indicated one of the following outcomes relating to the primary infection under study: Clinical Success: participant was alive; the ABSSSI sufficiently resolved such that further antibacterial therapy is not needed. Clinical Failure: any of the following: (1)Investigator discontinued study treatment and indicated that the ABSSSI had responded inadequately such that alternative (rescue) non-study antibacterial therapy was needed; (2)participant received antibacterial therapy for a different infection that may be effective for the ABSSSI under study; (3) participant developed an adverse event (AE) that required discontinuation of study treatment before completion of the planned treatment regimen; (4) unplanned major surgical treatment for the ABSSSI under study; (5) participant died of any cause up to the specified visit. Indeterminate: study data are unavailable for evaluation of efficacy for any reason (eg, missing data, lost to follow-up).
Time frame: 7 to 14 days after the end of study treatment
Investigator's Assessment of Clinical Response at the End of Treatment (EOT) Visit in the mITT Population
At the EOT Visit the investigator indicated one of the following outcomes relating to the primary infection under study: Clinical Success: participant was alive; the ABSSSI sufficiently resolved such that further antibacterial therapy is not needed. Clinical Failure: any of the following: (1)Investigator discontinued study treatment and indicated that the ABSSSI had responded inadequately such that alternative (rescue) non-study antibacterial therapy was needed; (2)participant received antibacterial therapy for a different infection that may be effective for the ABSSSI under study; (3) participant developed an adverse event (AE) that required discontinuation of study treatment before completion of the planned treatment regimen; (4) unplanned major surgical treatment for the ABSSSI under study; (5) participant died of any cause up to the specified visit. Indeterminate: study data are unavailable for evaluation of efficacy for any reason (eg, missing data, lost to follow-up).
Time frame: After a minimum of 7 days up to 14 days of study treatment
Investigator's Assessment of Clinical Response at the End of Treatment (EOT) Visit in the Micro-ITT Population
At the EOT Visit the investigator indicated one of the following outcomes relating to the primary infection under study: Clinical Success: participant was alive; the ABSSSI sufficiently resolved such that further antibacterial therapy is not needed. Clinical Failure: any of the following: (1)Investigator discontinued study treatment and indicated that the ABSSSI had responded inadequately such that alternative (rescue) non-study antibacterial therapy was needed; (2)participant received antibacterial therapy for a different infection that may be effective for the ABSSSI under study; (3) participant developed an adverse event (AE) that required discontinuation of study treatment before completion of the planned treatment regimen; (4) unplanned major surgical treatment for the ABSSSI under study; (5) participant died of any cause up to the specified visit. Indeterminate: study data are unavailable for evaluation of efficacy for any reason (eg, missing data, lost to follow-up).
Time frame: After a minimum of 7 days up to 14 days of study treatment
AUC0-12h After First Infusion
Partial area under the concentration versus time curve from time zero to time 12 hours.
Time frame: 0 to 12 hours post-dose
AUC0-12h After Last Infusion
Partial area under the concentration versus time curve from time zero to time 12 hours
Time frame: 0 to 12 hours post-dose
Cmax After Last Infusion
Maximum observed concentration
Time frame: 57 to 60 minutes, 1.5 to 3 hours, 4 to 6 hours, 12 hours, after the last infusion
Cmax After First Infusion
Maximum observed concentration
Time frame: 57 to 60 minutes, 1.5 to 3 hours, 4 to 6 hours, 12 hours, after the first infusion
| Milestone | TNP-2092 | Vancomycin |
|---|---|---|
| Started | 80 | 40 |
| Completed | 63 | 35 |
| Not completed | 17 | 5 |
| Withdrew: Withdrawal by subject | 4 | 1 |
| Withdrew: Lost to follow-up | 13 | 4 |
Early clinical response is defined as responder meeting two criteria: (1) patient had at least a 20% reduction of acute bacterial skin and skin structure infection (ABSSSI) primary lesion size compared to baseline measurements; (2) patient did not die of any cause within 72 hours of the first dose of study treatment. An indeterminate classification is used for a response that could not be adequately inferred because study data are unavailable for evaluation of efficacy for any reason (eg, missing data, lost to follow-up, did not attend the EA clinic appointment), or if the early assessment visit is out of the 48 to 72 hours window after the intravenous study treatment starts.
| Participants | TNP-2092 | Vancomycin |
|---|---|---|
| Responder | 61 | 27 |
| Nonresponder | 4 | 3 |
| Indeterminate | 15 | 10 |
Early clinical response is defined as responder meeting two criteria: (1) patient had at least a 20% reduction of acute bacterial skin and skin structure infection (ABSSSI) primary lesion size compared to baseline measurements; (2) patient did not die of any cause within 72 hours of the first dose of study treatment. An indeterminate classification is used for a response that could not be adequately inferred because study data are unavailable for evaluation of efficacy for any reason (eg, missing data, lost to follow-up, did not attend the EA clinic appointment), or if the early assessment visit is out of the 48 to 72 hours window after the intravenous study treatment starts.
| Participants | TNP-2092 | Vancomycin |
|---|---|---|
| Responder | 60 | 27 |
| Nonresponder | 4 | 3 |
| Indeterminate | 14 | 10 |
Early clinical response is defined as responder meeting two criteria: (1) patient had at least a 20% reduction of acute bacterial skin and skin structure infection (ABSSSI) primary lesion size compared to baseline measurements; (2) patient did not die of any cause within 72 hours of the first dose of study treatment. An indeterminate classification is used for a response that could not be adequately inferred because study data are unavailable for evaluation of efficacy for any reason (eg, missing data, lost to follow-up, did not attend the EA clinic appointment), or if the early assessment visit is out of the 48 to 72 hours window after the intravenous study treatment starts.
| Participants | TNP-2092 | Vancomycin |
|---|---|---|
| Responder | 41 | 19 |
| Nonresponder | 3 | 2 |
| Indeterminate | 7 | 8 |
At the PTE Visit the investigator indicated one of the following outcomes relating to the primary infection under study: Clinical Success: participant was alive; the ABSSSI sufficiently resolved such that further antibacterial therapy is not needed. Clinical Failure: any of the following: (1)Investigator discontinued study treatment and indicated that the ABSSSI had responded inadequately such that alternative (rescue) non-study antibacterial therapy was needed; (2)participant received antibacterial therapy for a different infection that may be effective for the ABSSSI under study; (3) participant developed an adverse event (AE) that required discontinuation of study treatment before completion of the planned treatment regimen; (4) unplanned major surgical treatment for the ABSSSI under study; (5) participant died of any cause up to the specified visit. Indeterminate: study data are unavailable for evaluation of efficacy for any reason (eg, missing data, lost to follow-up).
| Participants | TNP-2092 | Vancomycin |
|---|---|---|
| Success | 62 | 31 |
| Failure | 2 | 3 |
| Indeterminate | 14 | 6 |
At the PTE Visit the investigator indicated one of the following outcomes relating to the primary infection under study: Clinical Success: participant was alive; the ABSSSI sufficiently resolved such that further antibacterial therapy is not needed. Clinical Failure: any of the following: (1)Investigator discontinued study treatment and indicated that the ABSSSI had responded inadequately such that alternative (rescue) non-study antibacterial therapy was needed; (2)participant received antibacterial therapy for a different infection that may be effective for the ABSSSI under study; (3) participant developed an adverse event (AE) that required discontinuation of study treatment before completion of the planned treatment regimen; (4) unplanned major surgical treatment for the ABSSSI under study; (5) participant died of any cause up to the specified visit. Indeterminate: study data are unavailable for evaluation of efficacy for any reason (eg, missing data, lost to follow-up).
| Participants | TNP-2092 | Vancomycin |
|---|---|---|
| Success | 40 | 23 |
| Failure | 2 | 1 |
| Indeterminate | 9 | 5 |
At the EOT Visit the investigator indicated one of the following outcomes relating to the primary infection under study: Clinical Success: participant was alive; the ABSSSI sufficiently resolved such that further antibacterial therapy is not needed. Clinical Failure: any of the following: (1)Investigator discontinued study treatment and indicated that the ABSSSI had responded inadequately such that alternative (rescue) non-study antibacterial therapy was needed; (2)participant received antibacterial therapy for a different infection that may be effective for the ABSSSI under study; (3) participant developed an adverse event (AE) that required discontinuation of study treatment before completion of the planned treatment regimen; (4) unplanned major surgical treatment for the ABSSSI under study; (5) participant died of any cause up to the specified visit. Indeterminate: study data are unavailable for evaluation of efficacy for any reason (eg, missing data, lost to follow-up).
| Participants | TNP-2092 | Vancomycin |
|---|---|---|
| Success | 68 | 31 |
| Failure | 2 | 3 |
| Indeterminate | 8 | 6 |
At the EOT Visit the investigator indicated one of the following outcomes relating to the primary infection under study: Clinical Success: participant was alive; the ABSSSI sufficiently resolved such that further antibacterial therapy is not needed. Clinical Failure: any of the following: (1)Investigator discontinued study treatment and indicated that the ABSSSI had responded inadequately such that alternative (rescue) non-study antibacterial therapy was needed; (2)participant received antibacterial therapy for a different infection that may be effective for the ABSSSI under study; (3) participant developed an adverse event (AE) that required discontinuation of study treatment before completion of the planned treatment regimen; (4) unplanned major surgical treatment for the ABSSSI under study; (5) participant died of any cause up to the specified visit. Indeterminate: study data are unavailable for evaluation of efficacy for any reason (eg, missing data, lost to follow-up).
| Participants | TNP-2092 | Vancomycin |
|---|---|---|
| Success | 45 | 23 |
| Failure | 2 | 1 |
| Indeterminate | 4 | 5 |
Partial area under the concentration versus time curve from time zero to time 12 hours.
| h*ng/mL | TNP-2092 |
|---|---|
| AUC0-12h After First Infusion | 135000 ± 38200 |
Partial area under the concentration versus time curve from time zero to time 12 hours
| h*ng/mL | TNP-2092 |
|---|---|
| AUC0-12h After Last Infusion | 159000 ± 74200 |
Maximum observed concentration
| ng/mL | TNP-2092 |
|---|---|
| Cmax After Last Infusion | 38500 ± 13400 |
Maximum observed concentration
| ng/mL | TNP-2092 |
|---|---|
| Cmax After First Infusion | 37500 ± 13500 |
Collected over Adverse events were assessed from the first day of study treatment (day 1) to long-term follow-up visit(20 to 25 days after end of treatment), A Serious Adverse event (SAE) will be followed until resolution, stabilization, the event is otherwise explained, or the participant is lost to follow-up.. Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| TNP-2092 | 0/78 (0%) | 1/78 (1.3%) | 27/78 (34.6%) |
| Vancomycin | 0/39 (0%) | 2/39 (5.1%) | 11/39 (28.2%) |
| Event | TNP-2092 | Vancomycin |
|---|---|---|
| mental status changesPsychiatric disorders | 0/78 | 1/39 |
| left upper extremity abscess,dehydrationSkin and subcutaneous tissue disorders | 0/78 | 1/39 |
| MRSA bacteremia and worsening cellulitisSkin and subcutaneous tissue disorders | 1/78 | 0/39 |
| Event | TNP-2092 | Vancomycin |
|---|---|---|
| NauseaGastrointestinal disorders | 12/78 | 2/39 |
| CellulitisSkin and subcutaneous tissue disorders | 7/78 | 5/39 |
| VomitingGastrointestinal disorders | 6/78 | 2/39 |
| Wound infectionInfections and infestations | 2/78 | 2/39 |
| Age, Continuous(years) | TNP-2092 | Vancomycin | Total |
|---|---|---|---|
| Mean | 41.4 ± 11.72 | 42.7 ± 13.16 | 41.9 ± 12.18 |
| Sex: Female, Male(Participants) | TNP-2092 | Vancomycin | Total |
|---|---|---|---|
| Female | 19 | 14 | 33 |
| Male | 61 | 26 | 87 |
| Ethnicity (NIH/OMB)(Participants) | TNP-2092 | Vancomycin | Total |
|---|---|---|---|
| Hispanic or Latino | 32 | 17 | 49 |
| Not Hispanic or Latino | 48 | 23 | 71 |
| Unknown or Not Reported | 0 | 0 | 0 |
| Race (NIH/OMB)(Participants) | TNP-2092 | Vancomycin | Total |
|---|---|---|---|
| American Indian or Alaska Native | 1 | 3 | 4 |
| Asian | 0 | 0 | 0 |
| Native Hawaiian or Other Pacific Islander | 0 | 0 | 0 |
| Black or African American | 5 | 4 | 9 |
| White | 70 | 32 | 102 |
| More than one race | 0 | 0 | 0 |
| Unknown or Not Reported | 4 | 1 | 5 |
| Height(cm) | TNP-2092 | Vancomycin | Total |
|---|---|---|---|
| Mean | 173.5 ± 9.46 | 170.5 ± 8.32 | 172.5 ± 9.17 |
| Body mass index(kg/m^2) | TNP-2092 | Vancomycin | Total |
|---|---|---|---|
| Mean | 24.1 ± 2.98 | 24.8 ± 3.47 | 24.4 ± 3.15 |
| Weight(kg) | TNP-2092 | Vancomycin | Total |
|---|---|---|---|
| Mean | 72.8 ± 11.81 | 72.7 ± 14.43 | 72.8 ± 12.68 |
PDFs hosted by the registry, ClinicalTrials.gov.
Ran from Apr 2019 to primary completion in Sep 2020, 17 months.
Results were first posted in Dec 2023, 3 years 2 months after primary completion.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Nov 2023. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: TNP-2092
Gram-Positive Bacterial Infections →
TenNor Therapeutics Limited